{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-135212","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.200069+00:00","generated_at":"2026-05-29T04:44:41.762685+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program","bullets":["PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).","CRs observed in DLBCL (monotherapy and combo) and MCL (combo); responses in patients with prior CAR-T therapy.","Most common TEAE: neutropenia (48%, grade≥3: 46%); one DLT of tumor lysis syndrome at 24 mg/m2 dose.","Prelude will seek a partner for PRT2527 to focus resources on SMARCA degrader programs.","Data presented at 66th ASH Annual Meeting on Dec 11, 2024; 46 patients safety-evaluable as of Sep 17, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-135212","json":"https://secwatch.observer/filing/0000950170-24-135212.json","markdown":"https://secwatch.observer/filing/0000950170-24-135212.md","text":"https://secwatch.observer/filing/0000950170-24-135212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/0000950170-24-135212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/prld-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:44:41.762685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}